Dusan Stefoski

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson et al. · The Lancet Neurology · 2009 · 470 citations

Rheumatology, Radiological Disease Activity, Systemic Scleroderma +7

Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument

David Cella, Kelly K. Dineen, B. G. W. Arnason et al. · Neurology · 1996 · 404 citations

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj et al. · The Lancet · 2013 · 285 citations

Relapsing-remitting Multiple Sclerosis, Clinical Trials, Treatment Option +7

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Richard K. Burt, Ann Traynor, Richard M. Pope et al. · Blood · 1998 · 211 citations